(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2011 (12.05.2011)

PCT

(10) International Publication Number
WO 2011/056772 A1

(51) International Patent Classification:
C12P 21/08 (2006.01) *C12N 5/07* (2010.01)

(21) International Application Number:
PCT/US2010/055062

(22) International Filing Date:
2 November 2010 (02.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/258,051 4 November 2009 (04.11.2009) US
61/297,008 21 January 2010 (21.01.2010) US

(71) Applicant *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **PRESTA, Leonard, G.** [US/US]; 901 California Avenue, Palo Alto, CA 94304 (US).

(74) Agents: **TRIOLO, Thomas, A.** et al.; Merck, 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: ENGINEERED ANTI-TSLP ANTIBODY

```
Sequence 1     20 QVQLVQSGAEVKKPGASVKVSCKASGYIFTDYAMHWVRQAPGQGLEWMGTFIPLLDTSDY
Sequence 2      1 QVQLVQSGAEVKKPGASVKVSCKASGYIFTDYAMHWVRQAPGQGLEWMGTFIPLLDTSDY
                  ************************************************************

Sequence 1     80 AQKFQGRVTMTADTSTSTAYMELRSLRSDDTAVYYCARMGVTHSYVMDAWGQGTLVTVSS
Sequence 2     61 NQNFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARMGVTHSYVMDAWGQGTLVTVSS
                    * * ****** ***************************************************

Sequence 1    140 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
Sequence 2    121 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
                  ************************************************************

Sequence 1    200 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
Sequence 2    181 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
                  ************************************************************

Sequence 1    260 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
Sequence 2    241 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
                  ************************************************************

Sequence 1    320 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
Sequence 2    301 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
                  ************************************************************

Sequence 1    380 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
Sequence 2    361 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
                  ************************************************************

Sequence 1    440 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Sequence 2    421 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
                  *******************************
```

FIG.1

[Continued on next page]

WO 2011/056772 A1

GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

(57) Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, *e.g.*, in the treatment of inflammatory disorders and allergic inflammatory response.